31P The IOpener study: Tyrosine kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage non-small cell lung cancer

Karlijn De Joode ,B Pinedo,H.J.M Groen,E Kapiteijn,R Debets,J.G Aerts,R De Wijn,J.A Stigt,F Van Der Meer,T Van Doorn,D.p Hurkmans ,Sjoerd H Van Der Burg ,J.p Groten ,C.h Van Der Leest ,Ben Van Den Borne ,Marcel Van Den Heuvel ,Dianne M.a Van Den Heuvel ,E Verdegaal ,J.s Kloover ,R.h Mathijssen

doi:10.1016/j.iotech.2022.100136

31P The IOpener study: Tyrosine kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage non-small cell lung cancer

Karlijn De Joode , B Pinedo + Show 18 more

Open Access

https://doi.org/10.1016/j.iotech.2022.100136

Copy DOI

Journal: Immuno-Oncology and Technology	Publication Date: Dec 1, 2022
License type: cc-by-nc-nd

Affiliation: Erasmus MC Cancer Institute, Erasmus MC

#Advanced Stage Non-small Cell Lung #Stage Non-small Cell Lung Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Treatment with immune checkpoint inhibitors (ICIs) is successful, but only in a subset of patients with advanced stage non-small cell lung cancer (NSCLC). Blood-based kinase profiling of peripheral blood mononuclear cells (PBMCs) has previously shown its predictive value for response to ICI treatment in a discovery cohort (Hurkmans et al., JITC 2020). The aim of the current prospective study was to perform a blind validation of the predictive value of kinase activity profiles in PBMCs for ICI response in patients with NSCLC in a standardized setting.

Full Text